The Development of Cancer Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 74
Special Issue Editor
Interests: cancer immunotherapy; biomarker; CAR-T; Immune checkpoint inhibitor; pancreatic cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The clinical development of cancer immunotherapy has been progressing rapidly, and since the Nobel Prize in Physiology or Medicine in 2018 was awarded in this area, it has been attracting more attention than ever before and is expected to develop further in the future. Immune checkpoint inhibitors were developed as drugs with a completely different mechanism to conventional chemotherapy for cancer patients, and their therapeutic effects were characterized not only by tumor shrinkage, but also by the long-term survival of cancer patients, which had a strong impact on cancer treatment. On the other hand, as a result of numerous clinical trials, it was found that the efficacy of immune checkpoint inhibitors alone is only approximately 10–20%. Another cancer immunotherapy, genetically modified T-cell therapy, has shown high efficacy against hematological cancers, but its effectiveness against solid tumors is yet to be proven. The aim of this Special Issue is to further develop cancer immunotherapy.
Prof. Dr. Satoshi Wada
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- immune checkpoint inhibitors
- genetically modified T-cell therapy
- hematological cancers
- solid tumors
